Table 2.
Ongoing studies with a combination of immunotherapy and PARP inhibitors.
| Ongoing Phase III Studies | Immunotherapy | PARPi Agent | Patients | Outcome |
|---|---|---|---|---|
|
NCT03740165 (KEYLYNK-001) |
Pembrolizumab + CT | Olaparib (maintenance) | First-Line Treatment of Women with BRCA Non-mutated Advanced Ovarian Cancer | PFS |
|
NCT04191135 (KEYLYNK-009) |
Pembrolizumab | Olaparib | First-Line in Triple Negative Breast Cancer after induction CT + embrolizumabe | PFS |
|
NCT03737643 (DUO-O) |
Durvalumab +/- Bevacizumab | Olaparib (maintenance) | Newly diagnosed advanced ovarian, fallopian tube or primary peritoneal carcinoma or carcinosarcoma | PFS |
|
NCT03598270 (ANITA) |
Atezolizumab + Platinum-based Chemotherapy | Niraparib | Patients with Recurrent Ovarian Cancer | PFS |
| NCT03522246 (ATHENA) | Nivolumab | Rucaparib | Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy in Ovarian Cancer Patients | PFS |
|
NCT03642132 (JAVELIN OVARIAN PARP 100) |
Avelumab | Talazoparib | Maintenance therapy in Untreated Advanced Ovarian Cancer patients | PFS |
|
NCT03602859 (FIRST) |
Platinum-based Therapy With TSR-042 | Niraparib | First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer | PFS |
| Ongoing phase I/II trials | ||||
| NCT03101280 | Atezolizumab | Rucaparib | Participants with Advanced Gynecologic Cancers and TNBC | AE; DLTs Recommended Dose of Rucaparib3. |
| NCT02849496 | Atezolizumab | Olaparib | BRCA Mutant Non-HER2- Locally Advanced or Metastatic Breast Cancer | PFS; ORR |
| NCT03307785 | TSR-022 & TSR-042 | Niraparib | Patients with Advanced or Metastatic Cancer | DLT; AE; ORR3 |
| NCT03565991 (Javelin BRCA/ATM) | Avelumab | Talazoparib | Patients with BRCA or ATM Mutant metastatic Solid Tumors | OR; TTR; DOR; PFS; OS |
| NCT02660034 | Tislelizumab | Pamiparib | Subjects with Advanced Solid Tumors | AE; DLT; ORR; PFS; DOR; OS |
| NCT02484404 | Durvalumab | Olaparib and/or Cediranib | Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | ORR; RP2D |
CT, chemotherapy; BRCA, breast cancer gene; TNBC, triple-negative breast cancer; ATM, ataxia telangiectasia mutated; HER2, human epidermal growth factor 2 receptor; AE, adverse events; PSF, progression-free survival; ORR, overall response rate; DOR, duration of response; OR, objective response; TTR, time to tumor response; DLT, dose-limiting toxicities; RP2D, recommended phase 2 dose.